Tesamorelin

Tesamorelin is a stabilized synthetic peptide and an analog of GH–releasing hormone (GHRH 1–44). The peptide includes an N-terminal trans-3-hexenoic acid modification, which improves stability and limits enzymatic degradation. Tesamorelin is a 44–amino acid polypeptide that binds to GHRH receptors on pituitary somatotroph cells. This binding stimulates endogenous GH synthesis and promotes pulsatile GH secretion in research models. The peptide is supplied as lyophilized powder with ≥99% purity by HPLC analysis. Each vial contains 10 mg for laboratory research use. Researchers use tesamorelin to study the somatotropic axis, including endocrine signaling, metabolic regulation, fat distribution, and GH–IGF-1 pathways. Tesamorelin is intended only for in vitro and in vivo research. It is not approved for human consumption or therapeutic use.

Tesamorelin Mechanism of Action in Research Models

In preclinical studies, tesamorelin acts as a selective GHRH receptor agonist. It binds to GH–releasing hormone receptors on pituitary cells, activating Gs-protein signaling pathways. Activation increases intracellular cyclic AMP levels and protein kinase A activity, promoting transcription of GH genes. The result is enhanced pulsatile GH release. GH stimulates hepatic IGF-1 production. IGF-1 promotes lipolysis, limits adipocyte differentiation, and favors fat mobilization, especially in visceral tissue. The trans-3-hexenoic acid modification improves resistance to DPP-IV cleavage, extending peptide stability and supporting a more favorable pharmacokinetic profile than native GHRH.

Tesamorelin Peptide Sequence

Tesamorelin is a linear peptide with 44 amino acids and includes an N-terminal trans-3-hexenoyl modification.

Peptide sequence:

trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂

Chemical details include:

• Molecular formula: C₂₂₁H₃₆₆N₇₂O₆₇S
• Molecular weight: ~5135.78–5136 Da
• Key modification: N-terminal trans-3-hexenoyl group
• CAS number: 218949-78-1

This structure preserves full GHRH bioactivity and extends the half-life in experimental systems.

Tesamorelin Research

Tesamorelin has been widely studied in metabolic research. Early work focused on HIV-associated lipodystrophy, visceral adiposity, and endocrine dysfunction. Randomized controlled trials report VAT reduction of 15–18% over 26 weeks, with placebo groups showing increases in visceral fat. Extended studies observed sustained effects up to 52 weeks. Research also showed reductions in liver fat content, with some cohorts reporting decreases of nearly 80%. Improvements appeared in lipid profiles, insulin sensitivity markers, and aminotransferase levels in subjects with elevated baselines. Additional studies explore NAFLD and obesity-related insulin resistance. Tesamorelin increases IGF-1 levels dose-dependently, while pulsatile GH patterns remain intact, differing from continuous GH infusion models. Safety data indicate mostly mild injection-site reactions. Transient IGF-1 elevations require monitoring. No clear liver injury appeared in trials. Ongoing research examines long-term endocrine effects and receptor kinetics.

How to Store and Handle Tesamorelin

Tesamorelin is supplied as a lyophilized powder. Store unopened vials at 2–8°C, protected from light and moisture. Do not freeze the powder. Reconstitute using bacteriostatic water or sterile diluent under aseptic conditions, and refrigerate reconstituted solutions. Use solutions within established stability periods and follow protocol-specific guidelines. Always use sterile tools and proper protective equipment.

Disclaimer

Tesamorelin is an investigational research peptide intended only for laboratory and animal research. It is not approved for general human use. Regulatory approval exists only for specific prescription products. Research-grade tesamorelin is not approved for therapy or supplementation and falls under research chemical classifications, including WADA S0. Preclinical findings do not predict outcomes outside studied settings. No claims are made regarding safety or effectiveness in humans. Handle only in qualified research facilities with institutional oversight. Products are sold strictly for laboratory use only.

Referenced Citations

• Falutz J, et al. (2010). Metabolic effects of a GH-releasing factor in patients with HIV. Annals of Internal Medicine. 152(5):323–331.
• Gelato MC, et al. (2005). Effects of tesamorelin in HIV-infected patients with excess abdominal fat. Journal of Clinical Endocrinology & Metabolism. 90(9):5247–5253.
• Stanley TL, et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA.
• NCBI LiverTox: Tesamorelin – Mechanism, clinical use in HIV lipodystrophy, and safety profile (NBK548730).
• Additional insights from supplier data: Purity ≥99%, lyophilized form, research-only use.